🕒 Created · Updated

AstraZeneca releases positive results from two late-stage trials for experimental COPD drug tozorakimab

AstraZeneca released full results from two successful late-stage trials for its experimental biologic medicine, tozorakimab, which targets chronic obstructive pulmonary disease (COPD). The drug, administered once every four weeks, demonstrated a statistically significant reduction in moderate and severe COPD flare-ups for a broad population of patients, including both current and former smokers. In the OBERON and TITANIA trials, tozorakimab reduced moderate and severe exacerbations by 29% and 34% in former smokers, respectively, compared to a placebo group receiving inhaled standard of care. In the overall population of current and former smokers, the drug reduced flare-ups by 30% and 29%, respectively. The drug works by blocking a protein called IL-33, which drives inflammation and mucus production. Tozorakimab is currently under priority review by the Food and Drug Administration, with U.S. approval expected in the first quarter of 2027. AstraZeneca raised its peak annual sales forecast for the drug to more than $5 billion. The medicine is also being studied in Phase 2 and Phase 3 trials for severe asthma and severe viral lower respiratory tract disease.

Sources

Paywall and unreadable sources